ArticleMolecular and clinical oncology2018
Primary ovarian signet ring cell carcinoma: A rare case report.
Article in Molecular and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Survival Outcomes in Stage IV Gastric Cancer Patients with Krukenberg Tumors: A Systematic Review and Meta Analysis.Journal of gastrointestinal cancer · 2024Pooled it
- A Rare Case of Primary Ovarian Mucinous Carcinoma with Signet-Ring Cells and Literature Review.Turk patoloji dergisi · 2026Review
- Primary Ovarian Poorly Differentiated Adenocarcinoma with Signet-Ring Cells: A Case Report and Literature Review.Journal of clinical medicine · 2025Article
- A prognostic nomogram for women with primary ovarian signet-ring cell carcinoma.Annals of translational medicine · 2021Article
- Primary mucinous ovarian tumors vs. ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics.Diagnostic pathology · 2021Review
- Epidemiology of Signet Ring Cell Adenocarcinomas.Cancers · 2020Article
- A case of primary ovarian signet-ring cell carcinoma treated with S-1/CDDP therapy.Journal of ovarian research · 2020Article
- Primary signet ring cell carcinoma with neuroendocrine differentiation arising in mucinous borderline tumor of the ovary.Gynecologic oncology reports · 2020Article
- Ovarian Mixed Malignant Brenner-Mucinous Tumor with Signet Ring Cells.Case reports in pathology · 2020Article
- Poorly differentiated mucinous carcinoma with signet ring cells in an ovarian endometriotic cyst: a case report.Diagnostic pathology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Signet ring cell carcinoma (SRCC) of the ovary is most commonly metastatic from a primary lesion. Primary ovarian SRCC is rare, and the distinction between primary and metastatic SRCC of the ovary may be difficult. We herein present a case of primary SRCC of the ovary in a 54-year-old woman presenting with a right ovarian mass sized 20.5×16.5×11.5 cm. Total abdominal hysterectomy with bilateral salpingo-oophorectomy, partial omentectomy and incidental appendectomy were performed. Upon histological examination, mucinous carcinoma composed predominantly of signet ring cells was observed in the right ovary. The results of immunohistochemical examination included diffuse positivity for cytokeratin (CK)7 and CK20, but the tumor was negative for estrogen receptor, progesterone receptor, caudal type homeobox 2 and Wilms' tumor gene 1. A preoperative computed tomography (CT) scan of the abdomen and a postoperative positron emission tomography-CT scan did not reveal any suspicious extraovarian lesions. Based on the histological and clinicoradiological examinations, this case was diagnosed as a primary ovarian SRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.